Citigroup Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $58

Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $45 to $58.